Back to Results
First PageMeta Content
Janus kinase inhibitor / Placebo / Thrombocytosis / Polycythemia vera / Splenomegaly / Leukemia / Medicine / Ruxolitinib / Myelofibrosis


ruxolitinib (as phosphate), 5mg, 15mg, & 20mg tablets (Jakavi®) SMC No[removed]Novartis Pharmaceuticals UK Ltd. 06 February 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above produc
Add to Reading List

Open Document

File Size: 211,95 KB

Share Result on Facebook

Company

Patient Access Scheme Assessment Group / Therapeutic Committees / SMC No. (867/13) Novartis Pharmaceuticals UK Ltd. / Cooperative Oncology Group / Drug / 8D / ITT / /

Country

United Kingdom / Scotland / /

Currency

GBP / /

Event

Man-Made Disaster / FDA Phase / /

IndustryTerm

treatment of splenomegaly or symptoms / above product / magnetic resonance imaging / therapy for the treatment of disease / objective symptom monitoring tool / Treatment of Cancer / pharmaceutical / therapy for myelofibrosis-related constitutional symptoms / /

MedicalCondition

abdominal pain / chronic idiopathic myelofibrosis / insomnia / thrombocytosis / Cancer / disease / Myeloproliferative Neoplasm Symptom Assessment Form / neoplasm / polycythaemia vera myelofibrosis / neutropenia / pruritis / thrombocytopenia / primary myelofibrosis / Leukaemia / pain / fatigue / Portal hypertension / varices / disorder / infection / cough / essential thrombocythaemia myelofibrosis / myelofibrosis / /

MedicalTreatment

alternative therapy / bone marrow transplant / experimental therapy / /

Organization

European Union / British Committee / NHS / /

Position

investigator / Vice Chairman / physician / Major / /

Product

prednisolone / 20mg / danazol / prednisone / JAK2 / /

PublishedMedium

Baseline / /

Technology

magnetic resonance imaging / tomography / transplantation / simulation / MRI / /

SocialTag